IMMUNITYBIO, INC. (IBRX) Profit Breakdown
- 2026-06-30: Reportable $50.94M.
- 2025-06-30: Reportable $26.29M.
Complete filed revenue-to-profit bridge showing gross profit, operating income, pre-tax income and net income.
- Available history
- 2013-12-31 to 2026-06-30
- Data captured
Profit by product
Gross profit: each quarter (3 month)
| Quarter end | Reportable |
|---|
| 2026-06-30 | $50.94M |
|---|
| 2025-06-30 | $26.29M |
|---|
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest: each quarter (3 month)
| Quarter end | Reportable |
|---|
| 2026-06-30 | -$230.39M |
|---|
| 2025-06-30 | -$92.31M |
|---|
Net Income (Loss) Attributable to Parent: each quarter (3 month)
| Quarter end | Reportable |
|---|
| 2026-06-30 | -$230.38M |
|---|
| 2025-06-30 | -$92.56M |
|---|
Nonoperating Income (Expense): each quarter (3 month)
| Quarter end | Reportable |
|---|
| 2026-06-30 | -$168.69M |
|---|
| 2025-06-30 | -$21.02M |
|---|
Operating income: each quarter (3 month)
| Quarter end | Reportable |
|---|
| 2026-06-30 | -$61.70M |
|---|
| 2025-06-30 | -$71.28M |
|---|